Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Somedeb Ball

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Blood Advances|February 7, 2022
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosisMargherita Maffioli, Barbara Mora, Somedeb Ball, et al.
Leukemia|November 12, 2024
Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort studyDouglas Tremblay, Clifford Csizmar, Courtney D DiNardo, et al.
Haematologica|May 7, 2026
Myelodysplastic syndrome with concomitant <i>SF3B1</i> mutation and deletion of chromosome 5 long arm: outcomes and response to treatmentRami Komrokji, Zaker Schwabkey, Zena Komrokji, et al.
Blood Cancer Discovery|February 11, 2026
Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating AgentsDimitrios Drekolias, Fatima Tuz Zahra, Caroline Fileni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2024
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic SyndromesCristina Astrid Tentori, Caterina Gregorio, Marie Robin, et al.
Blood Cancer Journal|June 29, 2026
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE databaseJan Philipp Bewersdorf, Tariq Kewan, Luca Lanino, et al.
The Lancet. Haematology|October 11, 2024
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic SyndromesRami S Komrokji, Luca Lanino, Somedeb Ball, et al.
Hemasphere|June 24, 2026
Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS)Giulia Maggioni, Gabriele Todisco, Elisabetta Sauta, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Blood Advances|February 7, 2022
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosisMargherita Maffioli, Barbara Mora, Somedeb Ball, et al.
Leukemia|November 12, 2024
Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort studyDouglas Tremblay, Clifford Csizmar, Courtney D DiNardo, et al.
Haematologica|May 7, 2026
Myelodysplastic syndrome with concomitant <i>SF3B1</i> mutation and deletion of chromosome 5 long arm: outcomes and response to treatmentRami Komrokji, Zaker Schwabkey, Zena Komrokji, et al.
Blood Cancer Discovery|February 11, 2026
Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating AgentsDimitrios Drekolias, Fatima Tuz Zahra, Caroline Fileni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2024
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic SyndromesCristina Astrid Tentori, Caterina Gregorio, Marie Robin, et al.
Blood Cancer Journal|June 29, 2026
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE databaseJan Philipp Bewersdorf, Tariq Kewan, Luca Lanino, et al.
The Lancet. Haematology|October 11, 2024
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic SyndromesRami S Komrokji, Luca Lanino, Somedeb Ball, et al.
Hemasphere|June 24, 2026
Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS)Giulia Maggioni, Gabriele Todisco, Elisabetta Sauta, et al.
Pageof 8